Scholarlink

Background and Objectives <p>The prevalence of novel therapeutic markers identified in breast carcinoma in different patient populations is important to acknowledge their molecular diversity. The present study was therefore carried out with the aim of identifying signal transducers and their activators (STAT) 1 and 3, along with their activated products, in invasive breast carcinoma (IBC) of no special type (IBC-NST).</p> Methods <p>This was a prospective observational study in which STAT 1 and 3, as well as their activation, were examined by immunohistochemistry (IHC) in relation to clinico-pathological variables, molecular classification, and BRCA1 status in 222 IBC-NST.</p> Results <p>Mean age was 47.85, SD 10.95 years, with triple-negative breast cancer (TNBC) being the most common. 84.79% cases were positive for STAT 3 (<i>n</i> = 184/217) and only 38.12% (<i>n</i> = 32/83) displayed STAT 1 expression. Activation of STAT 1 and 3 was seen in 11.6% (<i>n</i> = 5/43) for STAT 1 and 38.55% (<i>n</i> = 32/83) cases for STAT 3. Molecular subtypes displayed significant correlation with respect to STAT 3 expression (<i>p</i> = 0.019). Cases with STAT3 activation showed a higher tumour grade (χ² = 4.916, <i>p</i> = 0.027). A significant number of cases with STAT 1 activation belonged to the TNBC group (4/5; 80%). Though not significant, 50% (16/32) of pSTAT3-expressing cases were TNBCs. All STAT 1 activated (χ²=4.047, <i>p</i> = 0.044) and 56.25% of STAT 3 activated (χ²=0.532, <i>p</i> = 0.466) tumours displayed BRCA1 loss by IHC.</p> Conclusion <p>Our data suggest that a substantial percentage of women with breast cancer in our region display STAT 1 and 3 immunoexpression and activation, with many belonging to TNBC. Hence, treatment with STAT inhibitors could play a role in the management of these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunoexpression and Activation of STAT1 and STAT3 in Invasive Breast Carcinoma No Special Type: Implications for Triple-Negative Breast Cancer and BRCA1 Status

  • 期刊论文

  • 发表日期：

    2026年2月9日

查看全文
  • Preeti Agarwal,
  • Ann Thomas,
  • Babli Gupta,
  • Shalini Bhalla,
  • Sameer Gupta,
  • Kulranjan Singh,
  • Ajay Km Singh,
  • Madhu Mati Goel

摘要

Background and Objectives

The prevalence of novel therapeutic markers identified in breast carcinoma in different patient populations is important to acknowledge their molecular diversity. The present study was therefore carried out with the aim of identifying signal transducers and their activators (STAT) 1 and 3, along with their activated products, in invasive breast carcinoma (IBC) of no special type (IBC-NST).

Methods

This was a prospective observational study in which STAT 1 and 3, as well as their activation, were examined by immunohistochemistry (IHC) in relation to clinico-pathological variables, molecular classification, and BRCA1 status in 222 IBC-NST.

Results

Mean age was 47.85, SD 10.95 years, with triple-negative breast cancer (TNBC) being the most common. 84.79% cases were positive for STAT 3 (n = 184/217) and only 38.12% (n = 32/83) displayed STAT 1 expression. Activation of STAT 1 and 3 was seen in 11.6% (n = 5/43) for STAT 1 and 38.55% (n = 32/83) cases for STAT 3. Molecular subtypes displayed significant correlation with respect to STAT 3 expression (p = 0.019). Cases with STAT3 activation showed a higher tumour grade (χ² = 4.916, p = 0.027). A significant number of cases with STAT 1 activation belonged to the TNBC group (4/5; 80%). Though not significant, 50% (16/32) of pSTAT3-expressing cases were TNBCs. All STAT 1 activated (χ²=4.047, p = 0.044) and 56.25% of STAT 3 activated (χ²=0.532, p = 0.466) tumours displayed BRCA1 loss by IHC.

Conclusion

Our data suggest that a substantial percentage of women with breast cancer in our region display STAT 1 and 3 immunoexpression and activation, with many belonging to TNBC. Hence, treatment with STAT inhibitors could play a role in the management of these patients.